Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome

Exp Neurol. 2006 Jul;200(1):256-61. doi: 10.1016/j.expneurol.2006.02.005. Epub 2006 Apr 19.

Abstract

The Ts65Dn mouse, an adult model of Down syndrome displays behavioral deficits consistent with a dysfunctional hippocampus, similar to that seen with DS. In looking for mechanisms underlying these performance deficits, we have assessed adult neurogenesis in the dentate gyrus of Ts65Dn. Under untreated conditions, Ts65Dn mice (2-5 months old) showed markedly fewer BrdU-labeled cells than euploid animals. Chronic antidepressant treatment for over 3 weeks with the serotonin selective reuptake inhibitor, fluoxetine, increased neurogenesis in the Ts65Dn to comparable levels seen in the euploid by augmenting both proliferation and survival of BrdU-labeled cells in the subgranular layer and granule cell layer of the hippocampus, respectively.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation / drug effects*
  • Cell Differentiation / physiology
  • Disease Models, Animal*
  • Down Syndrome / drug therapy*
  • Down Syndrome / pathology*
  • Down Syndrome / psychology
  • Female
  • Fluoxetine / pharmacology*
  • Fluoxetine / therapeutic use
  • Hippocampus / cytology
  • Hippocampus / drug effects*
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neurons / cytology
  • Neurons / drug effects*
  • Neuropsychological Tests

Substances

  • Fluoxetine